LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. However, there are differences in the substances' molecular structures and receptor activation profiles which may induce differential subjective effects. To date, there are no modern studies comparing LSD, psilocybin and mescaline directly within the same clinical study and research subjects using validated psychometric tools. Therefore, the LPM-Study compares the acute effects of LSD, psilocybin, mescaline and placebo in a double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions: 1) 100 μg LSD, 2) 20 mg psilocybin, 3) 300 or 500 mg mescaline, and 4) placebo.
LSD (lysergic acid diethylamide), psilocybin (the active substance in "magic mushrooms") and mescaline (the active substance in Peyote and San Pedro cacti) are serotonergic hallucinogens widely used for recreational and/or ethnomedical purposes. LSD, psilocybin and mescaline are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. However, there are differences in their molecular structures (LSD: ergoline, psilocybin: tryptamine; mescaline: phenethylamine)and receptor activation profiles which may induce different subjective effects. To date, there are no modern studies comparing these three substances directly within the same clinical study and research subjects using validated psychometric tools. Therefore, the LPM-Study compares the acute effects of LSD, psilocybin, mescaline and placebo in a double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions: 1) 100 μg LSD, 2) 20 mg psilocybin, 3) 300 or 500 mg mescaline, and 4) placebo. The main objective of this study is to determine whether LSD, psilocybin and mescaline produce qualitatively similar subjective alterations of mind and associated brain activity patterns despite their unique receptor activation profiles. The study investigates psychological (psychometry), physiological and neuronal (magnetic resonance imaging) variables. The LPM-Study provides insight into the acute effects profiles of three serotonergic hallucinogens. It will enhance the understanding of psychedelic-induced altered states of consciousness in humans and will be relevant for the fields of psychiatry, psychology, and forensic toxicology.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
32
LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
Psilocybin 20 mg per os, single dose
Mescaline 300 mg or 500 mg per os, single dose
Placebo (Mannitol)
University Hospital Basel, Clinical Trial Unit
Basel, Canton of Basel-City, Switzerland
5 Dimensions of Altered States of Consciousness (5D-ASC)
5D-ASC subscale ratios
Time frame: 18 months
fMRI resting state functional connectivity (RSFC)
Spontaneous low-frequency fluctuations in BOLD signal during resting state
Time frame: 18 months
Visual Analog Scale (VAS)
Assesses the intensity and duration of subjective effects on a scale from 0% - 100% with higher scores representing more intense effects
Time frame: 18 months
States of Consciousness questionnaire (SCQ)
Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely")
Time frame: 18 months
Blood pressure
Assessment of sympathetic activation
Time frame: 18 months
Heart rate
Assessment of sympathetic activation
Time frame: 18 months
Body temperature
Assessment of sympathetic activation
Time frame: 18 months
Pupil size
Assessment of sympathetic activation
Time frame: 18 months
Drug plasma levels
Plasma levels of investigational drugs
Time frame: 18 months
Oxytocin levels
Levels of oxytocin in blood plasma
Time frame: 18 months
Blood-derived neurotrophic factor (BDNF)
Blood plasma levels of BDNF
Time frame: 18 months
Renal clearance values
Renal clearance values of investigational drugs through urine recovery
Time frame: 18 months
NEO-Five-Factor-Inventory (NEO-FFI)
Assesses personality traits
Time frame: 18 months
Freiburger Persönlichkeitsinventar (FPI)
Assesses personality traits
Time frame: 18 months
Saarbrücker Persönlichkeitsfragebogen (SPF)
Assesses personality traits
Time frame: 18 months
Adjective Mood Rating Scale (AMRS)
Assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely"
Time frame: 18 months
Mysticism Scale (MS)
Assesses the occurrence and intensity of mystical qualities in altered states of consciousness on a 9-point Likert scale ranging from -4 ("extremely inapplicable") to +4 ("extremely applicable"), with higher values indicating a more intense experience
Time frame: 18 months
Elliot Humility Scale (EHS)
Assesses the personality trait humility through 13 items on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree"
Time frame: 18 months
Jankowski Humility Scale (JHS)
Assesses the personality trait humility through 18 items on a 5-point Likert scale ranging from "not at all" to "strongly"
Time frame: 18 months
Arnett Inventory of Sensation Seeking (AISS-d)
Assesses personality traits
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.